{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-113966","form_type":"8-K","ticker":"QURE","cik":"0001590560","company_name":"uniQure N.V.","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.312878+00:00","generated_at":"2026-06-22T13:54:53.728462+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"uniQure Q3 net loss $47.9M; DSMB recommends resuming higher-dose AMT-130 enrollment","bullets":["Net loss $47.9M ($1.02/share) vs $36.5M ($0.79) in Q3 2021; revenue $1.4M down from $2.0M.","Cash $440.3M as of Sep 30, 2022; expected to fund operations into H1 2025.","DSMB recommends resuming higher-dose AMT-130 enrollment in European Phase Ib/II after SUSARs resolved.","BLA for etranacogene dezaparvovec under FDA priority review; EMA issued GMP certificate.","IND-enabling studies initiated for AMT-260 (epilepsy) and AMT-191 (Fabry); submissions expected 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-113966","json":"https://secwatch.observer/filing/0001104659-22-113966.json","markdown":"https://secwatch.observer/filing/0001104659-22-113966.md","text":"https://secwatch.observer/filing/0001104659-22-113966.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590560/000110465922113966/0001104659-22-113966-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590560/000110465922113966/tm2229521d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T13:54:53.728462+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"20121c861cb51d5bc16875ba45a7cd5c7a326bac","claim":"uniQure N.V. reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"On November 2, 2022, uniQure N.V. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022 and highlighting company progress.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590560/000110465922113966/0001104659-22-113966-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}